Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Origin and invasion of the emerging infectious pathogen Sphaerothecum destruens.

Sana S, Hardouin EA, Gozlan RE, Ercan D, Tarkan AS, Zhang T, Andreou D.

Emerg Microbes Infect. 2017 Aug 23;6(8):e76. doi: 10.1038/emi.2017.64.

2.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.

Cancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.

3.

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.

Chong CR, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Jänne PA.

Clin Cancer Res. 2017 Jan 1;23(1):204-213. doi: 10.1158/1078-0432.CCR-15-1601. Epub 2016 Jul 1.

4.

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck MJ.

Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.

5.

Arterial disease and vascular access in diabetic patients.

Baktiroglu S, Yanar F, Ozata IH, Oner G, Ercan D.

J Vasc Access. 2016 Mar;17 Suppl 1:S69-71. doi: 10.5301/jva.5000532. Epub 2016 Mar 6. Review.

PMID:
26951909
6.

Effects of fed-batch and continuous fermentations on human lysozyme production by Kluyveromyces lactis K7 in biofilm reactors.

Ercan D, Demirci A.

Bioprocess Biosyst Eng. 2015 Dec;38(12):2461-8. doi: 10.1007/s00449-015-1483-7. Epub 2015 Oct 12.

PMID:
26458820
7.

Recent advances for the production and recovery methods of lysozyme.

Ercan D, Demirci A.

Crit Rev Biotechnol. 2016 Dec;36(6):1078-1088. Epub 2015 Sep 18. Review.

PMID:
26383819
8.

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Jänne PA.

Cancer Res. 2015 Aug 1;75(15):3139-46. doi: 10.1158/0008-5472.CAN-14-3771. Epub 2015 Jun 5.

9.

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2015 Sep;5(9):960-971. doi: 10.1158/2159-8290.CD-15-0063. Epub 2015 Jun 2.

10.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA.

Clin Cancer Res. 2015 Sep 1;21(17):3913-23. doi: 10.1158/1078-0432.CCR-14-2789. Epub 2015 May 6.

11.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR.

Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.

12.

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.

Cell. 2015 Feb 26;160(5):977-989. doi: 10.1016/j.cell.2015.01.042.

13.

Evidence of threat to European economy and biodiversity following the introduction of an alien pathogen on the fungal-animal boundary.

Ercan D, Andreou D, Sana S, Öntaş C, Baba E, Top N, Karakuş U, Tarkan AS, Gozlan RE.

Emerg Microbes Infect. 2015 Sep 2;4:e52. doi: 10.1038/emi.2015.52.

14.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.

Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. doi: 10.1073/pnas.1403438111. Epub 2014 Oct 27.

15.

Pharmacological targeting of the pseudokinase Her3.

Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS.

Nat Chem Biol. 2014 Dec;10(12):1006-12. doi: 10.1038/nchembio.1658. Epub 2014 Oct 19.

16.

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.

Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA.

Clin Cancer Res. 2014 Dec 15;20(24):6551-8. doi: 10.1158/1078-0432.CCR-14-1337. Epub 2014 Oct 7.

17.

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.

Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA.

Mol Oncol. 2015 Jan;9(1):260-9. doi: 10.1016/j.molonc.2014.08.011. Epub 2014 Aug 29.

18.

Hepatitis B virus e antigen (HBeAg) may have a negative effect on dendritic cell generation.

Hatipoglu I, Ercan D, Acilan C, Basalp A, Durali D, Baykal AT.

Immunobiology. 2014 Dec;219(12):944-9. doi: 10.1016/j.imbio.2014.07.020. Epub 2014 Aug 7.

PMID:
25150150
19.

The gradient technique improves success rates in intrauterine insemination cycles of unexplained subfertile couples when compared to swim up technique; a prospective randomized study.

Karamahmutoglu H, Erdem A, Erdem M, Mutlu MF, Bozkurt N, Oktem M, Ercan DD, Gumuslu S.

J Assist Reprod Genet. 2014 Sep;31(9):1139-45. doi: 10.1007/s10815-014-0274-4. Epub 2014 Jun 11.

20.

Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH.

Karakaya C, Guzeloglu-Kayisli O, Hobbs RJ, Gerasimova T, Uyar A, Erdem M, Oktem M, Erdem A, Gumuslu S, Ercan D, Sakkas D, Comizzoli P, Seli E, Lalioti MD.

Mol Hum Reprod. 2014 Jul;20(7):630-43. doi: 10.1093/molehr/gau024. Epub 2014 Mar 25.

21.

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC.

Nat Med. 2013 Nov;19(11):1469-1472. doi: 10.1038/nm.3352. Epub 2013 Oct 27.

22.

Current and future trends for biofilm reactors for fermentation processes.

Ercan D, Demirci A.

Crit Rev Biotechnol. 2015 Mar;35(1):1-14. doi: 10.3109/07388551.2013.793170. Epub 2013 Aug 6. Review.

PMID:
23919241
23.

Production of human lysozyme in biofilm reactor and optimization of growth parameters of Kluyveromyces lactis K7.

Ercan D, Demirci A.

Appl Microbiol Biotechnol. 2013 Jul;97(14):6211-21. doi: 10.1007/s00253-013-4944-4. Epub 2013 May 9.

PMID:
23657582
24.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.

Cancer Res. 2013 Apr 15;73(8):2574-86. doi: 10.1158/0008-5472.CAN-12-1702. Epub 2013 Feb 22.

25.

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA.

Cancer Res. 2013 Jan 15;73(2):834-43. doi: 10.1158/0008-5472.CAN-12-2066. Epub 2012 Nov 19.

26.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7.

27.

Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.

Yılmaz Ü, Gücüyener K, Atak A, Aral A, Gürkaş E, Demir E, Serdaroğlu A.

Pediatr Neurol. 2012 Sep;47(3):171-6. doi: 10.1016/j.pediatrneurol.2012.05.027. Erratum in: Pediatr Neurol. 2013 Mar;48(3):257. Ünsal, Yılmaz, [corrected to Yılmaz, Ünsal]; Kıvılcim, Gücüyener [corrected to Gücüyener, Kıvılcim]; Ayşegül, Atak [corrected to Atak, Ayşegük]; Arzu, Aral [corrected to Aral, Arzu]; Esra, Gürkaş corrected to [Gürkaş, Esra]; Ercan, Demi.

PMID:
22883281
28.

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.

Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK.

Cancer Res. 2012 Jul 1;72(13):3302-11. doi: 10.1158/0008-5472.CAN-11-3720. Epub 2012 May 2.

29.

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jänne PA, Stephens PJ.

Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.

30.

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA.

Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.

31.

Physicochemical, textural, volatile, and sensory profiles of traditional Sepet cheese.

Ercan D, Korel F, Yüceer YK, Kınık O.

J Dairy Sci. 2011 Sep;94(9):4300-12. doi: 10.3168/jds.2010-3941.

PMID:
21854903
32.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.

Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26.

33.

Discovery of selective irreversible inhibitors for EGFR-T790M.

Zhou W, Ercan D, Jänne PA, Gray NS.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):638-43. doi: 10.1016/j.bmcl.2010.12.036. Epub 2010 Dec 10.

34.

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.

Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA.

Oncogene. 2010 Apr 22;29(16):2346-56. doi: 10.1038/onc.2009.526. Epub 2010 Feb 1.

35.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA.

Nature. 2009 Dec 24;462(7276):1070-4. doi: 10.1038/nature08622.

Supplemental Content

Support Center